Sanofi and Regeneron Seal Eight Billion Dollar Immunology Alliance Expansion

French pharmaceutical giant Sanofi and U.S. biotech partner Regeneron Pharmaceuticals announced October 1 a major expansion of their long-standing collaboration, with Sanofi agreeing to pay Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to their alliance. The deal builds on more than two decades of partnership that has already established Dupixent as one of the world's most widely used antibody medicines, currently treating over 1.5 million patients across nine indications.

The expanded agreement centers on four Regeneron-invented antibodies targeting key immune system pathways: an interleukin-13 (IL-13) antibody, an IL-4xIL-13 bispecific, an interleukin-4 (IL-4) antibody, and an interleukin-4 receptor alpha (IL-4Rα) antibody. All four are long-acting formulations designed to require less frequent dosing than current treatments. REGN20423, the IL-13 antibody, is already in Phase 1 clinical trials for atopic dermatitis, while the other three antibodies are expected to enter clinical studies in 2027.

Building on Dupixent's Success

"The Regeneron-Sanofi alliance has been one of the most productive in biopharma history," said Leonard Schleifer, M.D., Ph.D., board co-chair, president and chief executive officer of Regeneron. "This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster. By expanding our alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved."

Dupixent, which was invented using Regeneron's proprietary VelocImmune technology, has transformed treatment for diseases driven by type 2 inflammation. The companies' clinical and commercial alliance dates to 2003 and has resulted in multiple approved medicines to date. The partnership structure that proved successful for Dupixent will continue with the new programs: Regeneron will lead research and development activities while Sanofi leads global commercial efforts, with both companies sharing development and commercialization costs as well as future profits on a 50-50 basis.

Strategic Shift for Sanofi

For Sanofi, the deal represents a significant strategic move as the company seeks to strengthen its innovation pipeline. "This is a deliberate first step in igniting Sanofi's innovation engine," said Belén Garijo, chief executive officer of Sanofi. "Our longstanding alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses. By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi's long-term future."

The agreement also includes an option for Regeneron to bring Sanofi's lunsekimig into the collaboration. Lunsekimig is an investigational bispecific Nanobody VHH therapy targeting TSLP and IL-13, currently in Phase 3 trials for chronic obstructive pulmonary disease. Regeneron can exercise this option upon completion of the Phase 3 trials.

Resolving Past Disputes

As part of the expanded alliance, the companies have settled their prior collaboration-related litigation, clearing the path for continued cooperation. George Yancopoulos, M.D., Ph.D., board co-chair, president and chief scientific officer at Regeneron and a principal inventor of Dupixent, emphasized the value of combining Regeneron's discovery capabilities with Sanofi's global reach.

"By combining Regeneron's world-class scientific discovery and antibody development expertise with Sanofi's global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology," Yancopoulos stated. The existing profit-sharing agreement regarding Dupixent will not change under the new deal, ensuring continuity for what has become one of the pharmaceutical industry's most successful partnerships.

The companies hosted a conference call for investors and analysts on October 1 to detail the agreement terms and answer questions about the strategic rationale behind the expansion. With Dupixent sales continuing to grow and four promising new programs now added to the collaboration, the Sanofi-Regeneron partnership appears positioned to remain a major force in immunology medicine for years to come.